Sreenivas Rao, MD
Medical Oncology · Florence, SCNPI 1942242102
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,687 of the $4,420 with a category attached, or 83.4%. It is spread thinly across 50 manufacturers, the largest accounting for just 8.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,059, 6.0 times the $178 reported in 2019.
Across 177 payments — averaging $24.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$364
- Novocure GmbH$250
- Astellas Pharma US Inc$234
- Amgen$218
- Lilly USA, LLC$218
- Bristol Myers Squibb$217
- plus $3K from 44 others
Across 1 payment — averaging $3975.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4K
What the payments were for
- Speaking & faculty fees$2506%
- Food & beverage$3,68783%
- Education$48411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cook$109
- Da Vinci Surgical System$102
How this compares
$4,420 in reported general payments places this provider in the 60th percentile of 29 medical oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 142 | $2,545,712 |
| CalquenceAcalabrutinib Maleate | 86 | $1,254,255 |
| Lenalidomide | 101 | $1,248,004 |
| ImbruvicaIbrutinib | 78 | $1,117,908 |
| XtandiEnzalutamide | 62 | $849,401 |
| PomalystPomalidomide | 34 | $770,627 |
| IbrancePalbociclib | 34 | $585,821 |
| PromactaEltrombopag Olamine | 43 | $579,804 |
| VerzenioAbemaciclib | 36 | $576,290 |
| Abiraterone Acetate | 137 | $411,022 |
| TagrissoOsimertinib Mesylate | 24 | $408,843 |
| TukysaTucatinib | 16 | $399,219 |
| VenclextaVenetoclax | 24 | $353,314 |
| XalkoriCrizotinib | 14 | $307,705 |
| LonsurfTrifluridine/Tipiracil Hcl | 16 | $229,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Thalomid | $217 | $2,665,640157 claims |
| AstraZenecaCalquence, Tagrisso | $140 | $1,663,097110 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $18 | $1,117,90878 claims |
| PfizerIbrance, Xalkori, Eliquis | $136 | $925,73689 claims |
| Astellas Pharma US IncXtandi | $234 | $849,40162 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $139 | $770,62734 claims |
| NovartisPromacta | $364 | $579,80443 claims |
| Lilly USA, LLCVerzenio | $218 | $576,29036 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $38 | $411,022137 claims |
| Seagen Inc.Tukysa | $207 | $399,21916 claims |
| AbbVieVenclexta | $109 | $353,31424 claims |
| Johnson & JohnsonErleada, Xarelto | $186 | $240,90454 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 29 medical oncology providers in South Carolina.
Other medical oncology in Florence
- Albert LockhartCharleston$54K
- Gene SaylorsCharleston$26K
- Mariam AlexanderCharleston$23K
- Theodore GourdinCharleston$21K
- John KaczmarCharleston$20K
- Eric NelsonSpartanburg$13K
- Karyn DyehouseSeneca$9K
- Kevin BeckerCharleston$9K
- Alaa MuslimaniRock Hill$9K
- Scott LindhorstCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.